Compare Abeona Therapeutics Inc (ABEO) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Dollar Tree, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Dollar Tree, Inc. trades at $123.67 (market cap $23.57B). The key difference: Dollar Tree, Inc. is far larger — about 63.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | DLTR | |
|---|---|---|
Market Cap | $373.32M | $23.57B |
Sector | Health | Health |
52-Week High | $7.23 | $141.21 |
52-Week Low | $4.17 | $85.04 |
Enterprise Value | $228.22M | $30.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Dollar Tree (DLTR) trades at $122.65, down 1.13% on the day, but maintains a bullish technical signal with strong moving average support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent news highlights a new $2.5 billion share repurchase authorization, signaling management confidence. Revenue for 2025 was $17.58 billion, though net income was impacted by a significant tax expense, resulting in a loss. Analyst consensus is bullish with a $130.70 price target, and institutional sentiment is positive amid evolving value retail strategies.
The outlook for DLTR is cautiously optimistic, driven by earnings momentum, share buybacks, and margin improvements. Key opportunities include multi-price strategy gains and cost controls, but risks involve traffic softness, inflationary pressures, and competitive threats. The stock's current valuation metrics, such as a P/E of 19.5, appear reasonable relative to growth prospects, though investors should monitor execution against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
